Patients With Poor Performance Status Still Benefit From Immunotherapy in MSI-H CRC

▸ TREATMENT

An international retrospective study of dMMR/MSI-H metastatic colorectal cancer patients found that immune checkpoint blockers produced durable responses even in patients with poor ECOG performance status, a group often excluded from treatment. (Clinical Colorectal Cancer)